Home › Systematic Review of 58 Publications of Real-World Use of GARDASIL Presented at EUROGIN Congress
 

Keywords :   


Systematic Review of 58 Publications of Real-World Use of GARDASIL Presented at EUROGIN Congress

2016-06-16 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that in a systematic review conducted of the global impact and effectiveness of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial reductions were observed in HPV 6/11/16/18-related infection, genital warts, Pap abnormalities and cervical pre-cancers. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review publications presented congress

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
03.05Navigator Paper Ups Offer for Accrual
03.05USDA urged to restore NASS surveys
03.05Dilo Hosts Open House
03.05Spate Releases Top-Rising Skin Care Ingredients Report with Grant Industries
More »